Wyeth, MediVas sign research agreement to develop haemophilia therapies |
|
|
|
Published
:
Mon, 05 Feb 2007 14:27 |
SAN DIEGO (AFX) - Wyeth Pharmaceuticals, a division of Wyeth, said it has signed a research collaboration with California-based biomaterials company MediVas LLC to develop, manufacture and commercialise biopharmaceuticals to treat haemophilia.Under the terms of the deal, Wyeth will develop, manufacture and market any products derived from the agreement, while MediVas will receive milestone payments based on net sales of products, they said.newsdesk@afxnews.comharCOPYRIGHTCopyright AFX News Limited 2006. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|